TY - JOUR
T1 - Cryptococcal Meningitis and AIDS
AU - Powderly, William G.
N1 - Funding Information:
Received 12 July 1993. Grant support: This work was supported in part by the National Institutes of Health (AI-25903). Reprints or correspondence: Dr. William G. Powderly, Box 8011, Washington University School of Medicine, 660 South Euclid, St. Louis, Missouri 63110.
PY - 1993/11
Y1 - 1993/11
N2 - Dr. William G. Powderly provides a comprehensive review of the state of our knowledge regarding cryptococcal infection in persons with infection due to human immunodeficiency virus type 1. The introduction of fluconazole and itraconazole increased insight into prognostic factors affecting these patients. The need to suppress this fungal infection in individuals with impaired immunity has greatly altered the management of cryptococcal meningitis; therapy for this condition was established by the landmark study conducted by the Mycosis Study Group in 1979 (Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in treatment of cryptococcal meningitis. N Engl J Med 1979;301:126-31). In this AIDS commentary Dr. Powderly clearly outlines the progress made through clinical investigations and the problems that remain to be resolved.
AB - Dr. William G. Powderly provides a comprehensive review of the state of our knowledge regarding cryptococcal infection in persons with infection due to human immunodeficiency virus type 1. The introduction of fluconazole and itraconazole increased insight into prognostic factors affecting these patients. The need to suppress this fungal infection in individuals with impaired immunity has greatly altered the management of cryptococcal meningitis; therapy for this condition was established by the landmark study conducted by the Mycosis Study Group in 1979 (Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in treatment of cryptococcal meningitis. N Engl J Med 1979;301:126-31). In this AIDS commentary Dr. Powderly clearly outlines the progress made through clinical investigations and the problems that remain to be resolved.
UR - http://www.scopus.com/inward/record.url?scp=0027521940&partnerID=8YFLogxK
U2 - 10.1093/clinids/17.5.837
DO - 10.1093/clinids/17.5.837
M3 - Article
C2 - 8286622
AN - SCOPUS:0027521940
SN - 1058-4838
VL - 17
SP - 837
EP - 842
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 5
ER -